Search companies

Live

NEUROTECH INTERNATIONAL LIMITED (ASX: NTI)

Health care · News and insights

Price unavailable

Latest NTI announcements

Announcement Insights

Neurotech Starts Phase 3 Autism Trial With Funding Intended to Reach Data Readout

Neurotech has begun dosing patients in its pivotal Phase 3 autism trial, with funding expected to support development through the top-line readout. The October 28 update also reported US FDA clearance to begin a proposed clinical program, patent allowances and financing commitments; shareholders later approved placement-related resolutions at the AGM.}

Updated 11 Nov 2026, 01:45 PM Sydney time
Share
SourcesChange of Director's Interest NoticeFinal Director's Interest NoticeResults of MeetingQuarterly Activities/Appendix 4C Cash Flow Report
Comments

Neurotech Director Departs With Related Entity Holding 4.6 Million Shares

2026-11-06 · Health care

NTI: $0.016 -5.88% · MC: $31M

Robert Maxwell Johnston ceased to be a director of Neurotech International Limited on 5 November; his final interest notice records 4.6 million ordinary shares held by a related entity. The company’s recent quarterly update said it expected to be funded through the top-line readout of its Phase 3 autism trial, which has begun dosing.

Updated 2026-11-06 15:09
Share
SourcesFinal Director's Interest Notice
Comments

Neurotech Shareholders Back All AGM Resolutions

2026-11-05 · Health care

NTI: $0.017 +6.25% · MC: $31M

Neurotech International shareholders passed all resolutions put to a poll at the annual meeting, including director elections, placement-related approvals and options issues. The company’s latest quarterly update said its pivotal Phase 3 autism trial had begun dosing and it had secured funding intended to support development through the trial’s top-line results.

Updated 2026-11-05 11:41
Share
SourcesResults of Meeting
Comments

Neurotech starts pivotal autism trial as US clearance and funding bolster NTI164 program

2026-10-28 · Health care

NTI: $0.018 -5.26% · MC: $31M

Neurotech International has dosed the first patient in its Phase 3 autism trial of NTI164, with all Australian sites initiated and up to 200 participants planned. The company also received US FDA clearance to begin a proposed clinical program and patent allowances, while securing a loan and placement commitments to support development; it says current funding is expected to last through the trial’s top-line data readout.

Updated 2026-10-28 08:26
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments